ClinicalTrials.gg
CompletedNCT01275469Updated Jan 12, 2011

Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.

A Phase 2 interventional study of GFT505 80mg and Placebo in Impaired Glucose Tolerance and Abdominal Obesity, sponsored by Genfit. Completed at 20 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-01-12.

Sponsored by Genfit · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Glucose Intolerance with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Glucose Intolerance · France.

Enrollment
7th of 12
47 · median 49
Started
2009
the only one that year
Phase 2
3 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
2 of 18
Genfit

Among the 18 studies in Glucose Intolerance with a site in France, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2009, is one of 3 in phase 2, and was the 6th registered.

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.

Browse Glucose Intolerance studies →

Open to participants now

3 of the 18 studies in Glucose Intolerance with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 70 Glucose Intolerance studies recruiting now, 14 (20%) set no upper age limit and 51 (73%) stop at 75 or younger; 10 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Glucose Intolerance with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of GFT505 80mg compared with placebo in improving Oral Glucose Tolerance Test (OGTT), in patients with impaired glucose tolerance and abdominal obesity, and to assess the tolerability and safety of once-a-day administrations of oral doses of GFT505 during 35 days.

Read the detailed description

The study period is 13 weeks maximum per patient : A screening period (1 to 6-weeks) will precede a 5-week double-blind treatment period and a 2-week follow-up period. The duration of the screening period will depend on the necessity to introduce a wash-out for lipid-lowering drugs : 4-week wash-out from statins and other lipid regulating drugs and 6-week wash-out from fibrates. During the screening period, patients will be asked to start or continue adequate diet and exercise.

03

Conditions studied

  • Impaired Glucose Tolerance
  • Abdominal Obesity

Keywords

  • Impaired Glucose tolerance
  • OGTT
  • PPARs
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Waist circumference ≥94cm for male, ≥ 80cm for female.
  • Fasting Plasma Glucose (FPG) between 110 and 126 mg/dl (between 6.1 and 7.0 mmol/l) within 6 months prior to the screening visit.
  • 2-hour glycaemia at OGTT (2hr after a 75g oral glucose load) ≥140 mg/dL (7.8 mmol/l).

Exclusion criteria

Exclusion Criteria:

  • (BMI) ≥ 40 kg/m².
  • Blood Pressure > 160 / 95 mmHg.
  • Known Type I or type II Diabetes Mellitus.
  • (HbA1c) >7%.
  • A fasting TG > 400mg/dl and a LDL-C > 220mg/dl.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    GFT505 80mg

    Drug: GFT505 80mg

  • Placebo comparator
    Matching placebo

    Drug: Placebo

Interventions

  • Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.

  • DrugPlacebo

    Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.

06

What researchers measure

Primary outcomes

  1. Oral Glucose test Tolerance (OGTT)

    To evaluate the change in plasma Glucose 2hr following oral glucose load from baseline to end point. Evaluation will be made during the selection period, prior any drug intake, and 4 weeks (28-34 days) after the first treatment intake.

    Time frame: 4 weeks

Secondary outcomes

  1. Volume oxygen maximal (VO2max)

    To evaluate the efficacy of GFT505 80mg compared with placebo in improving the VO2max at physical exercise test. Evaluation will be made during the selection period, prior any drug intake, and 5 weeks after the first treatment intake.

    Time frame: 5 weeks

  2. Respiratory parameters measured during the physical exercise test

    To describe the changes on others parameters measured during the physical exercise test : Volume carbon dioxide (VCO2), Respiratory quotient (RQ), Lactate concentration. Evaluation will be made during the selection period, prior any drug intake, and 5 weeks after the first treatment intake.

    Time frame: 5 weeks

  3. Fasting Glycemia and Insulinemia

    To describe the changes of fasting glycaemia and insulinemia in the two groups. Evaluation will be made the first day prior any drug intake, then 5 weeks after the first treatment intake.

    Time frame: 5 weeks

  4. HOMA index (Homeostasis Model Assessment)

    To describe the changes of HOMA index in the two groups. Evaluation will be made the first day prior any drug intake, then 5 weeks after the first treatment intake.

    Time frame: 5 weeks

  5. Lipids

    To describe the changes in Triglycerides (TG), High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C) and non High Density Lipoprotein Cholesterol (non-HDL-C) levels in the two groups. Evaluation will be made the first day prior any drug intake, then 2-3, and 4 weeks after the first treatment intake and 2 weeks after the last treatment intake (follow-up visit).

    Time frame: 5 weeks

07

Study locations

20 sites
  • Site n°31
    Angers, 49000, France
  • Site n°32
    Angers, 49000, France
  • Site n°36
    Angers, 49000, France
  • Site n°37
    Angers, 49000, France
  • Site n°34
    Angers, 49100, France
  • Site n°35
    Angers, 49100, France
  • Site n°39
    Angers, 49100, France
  • Site n°17
    Briollay, 49125, France
  • Site n°16
    Cholet, 49300, France
  • Site n°19
    Cholet, 49300, France
  • Site n°14
    le MESNIL en VALLEE, 49410, France
  • Site n°10
    Murs-erigne, 49610, France
  • Site n°12
    Murs-erigne, 49610, France
  • Site n°2
    Nantes, 44093, France
  • Site n°13
    Parcay Les Pins, 49390, France
  • Site n°1
    Paris, 75013, France
  • Site n°15
    Segre, 49500, France
  • Site n°11
    Thouars, 79100, France
  • Site n°30
    Tierce, 49125, France
  • Site n°18
    Vihiers, 49310, France
08

References and documents

Publications

  • Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, Baron M, Lucas A, Tailleux A, Hum DW, Ratziu V, Cariou B, Hanf R. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013 Dec;58(6):1941-52. doi: 10.1002/hep.26461. Epub 2013 Oct 29. PubMed 23703580 ↗
  • Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care. 2011 Sep;34(9):2008-14. doi: 10.2337/dc11-0093. Epub 2011 Aug 4. PubMed 21816979 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Dec 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2011
First posted
Jan 12, 2011
Start
Jun 2009
Primary completionActual
Dec 2009
CompletionActual
Jan 2010
Last update
Jan 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01275469
Lead sponsor
Genfit
First posted
Jan 12, 2011
Start date
Jun 2009
Primary completion
Dec 2009
Completion
Jan 2010
Last update
Jan 12, 2011

Study contacts

Rémy Hanf, Development Director
study director · GENFIT, France
Eric BRUCKERT, Pr.
study chair · University Hospital of Paris 6, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion